Hutchmed licenses KRAS-EGFR antibody-conjugate therapy from GSK
Hutchmed (China) Limited announced an exclusive licensing agreement with GSK covering the KRAS-EGFR antibody conjugate cancer therapy, including HMPL-A830.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Hutchmed announces licensing agreement with GSK for cancer therapy
HUTCHMED (China) Ltd (HKEX:13) said it has announced a licensing agreement with GSK for a Kras-EGFR-antibody conjugate cancer therapy.
Hutchmed announces licensing agreement with GSK for KRAS-EGFR therapy
Hutchmed said it has announced a licensing agreement with GSK for a KRAS-EGFR antibody conjugate cancer therapy.